 Business Wire India With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023, Fruquintinib Offers a Potential New Treatment Option for Patients with Refractory Metastatic Colorectal Cancer Licensing Agreement for Fruquintinib Strengthens Takedas Growing Oncology Portfolio Takeda TSE:4502NYSE:TAK today announced that it has entered into an exclusive licensing agreement... The post Takeda To Acquire Exclusive Worldwide ex-China License of HUTCHMEDs Fr... 